ArticleClinical research in cardiology : official journal of the German Cardiac Society2026
Incident atrial fibrillation and pyoderma gangrenosum: long-term thromboembolic, heart failure, and mortality risk.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundSystemic inflammation is increasingly linked to atrial arrhythmogenesis, yet arrhythmic risk and downstream cardiovascular complications remain poorly quantified for inflammatory diseases managed outside cardiology, including neutrophilic dermatoses such as pyoderma gangrenosum (PG).
methodsWe performed a global, large retrospective cohort study, including 147 healthcare organizations. Adults were included in three separate 1:1 propensity score-matched cohorts: (1) PG vs non-PG to assess incident AF and relevant arrhythmogenic heart disease; (2) PG with vs without AF to examine AF-related outcomes within PG; and (3) AF with vs without PG to examine the impact of PG within AF. Patients were followed for up to 5 years. Cox proportional hazards models, 90-day sensitivity analyses, and negative control outcomes enhance robustness.
resultsAmong 11,351 adults with PG and 2,132,938 without PG, matching yielded 11,216 well-balanced in each cohort. PG was associated with higher 5-year AF incidence (HR 1.61, p < 0.001). Among 1286 PG patients with AF and 10,834 without AF, 1133 pairs were matched. In the PG population, AF was associated with higher risks of systemic thromboembolism (HR 2.26, p < 0.001), heart failure (HR 4.19, p < 0.001), and all-cause mortality (HR 1.59, p < 0.001). In the AF population (1286 AF patients with PG; 2,400,413 without PG), PSM yielded 1265 pairs. PG was associated with increased systemic embolism (HR 2.03, p < 0.001), heart failure (HR 2.17, p < 0.001), and mortality (HR 1.53, p < 0.001). Negative control outcomes were consistently null; Cox proportional hazards models and sensitivity analyses showed similar patterns.
conclusionsPG was associated with increased incident AF and, among patients with AF, identified a high-risk phenotype with substantially higher thromboembolic events, heart failure, and mortality.
Indexed as
Identifiers
42545495What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.